Trials / Recruiting
RecruitingNCT06931626
Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer
Study of NMS-03305293, a Non-Trapping PARP1-Specific PARP Inhibitor in Relapsed Small Cell Lung Cancer
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Nerviano Medical Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label study of NMS-03305293 with Temozolomide (TMZ) in patients with Small Cell Lung Cancer (SCLC). The aim of this study is to determine the safety and tolerability, as well as to evaluate the anti-tumor efficacy and pharmacokinetics of NMS-03305293 in combination with TMZ.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NMS-03305293 | Route of administration: Oral |
| DRUG | Temozolomide | Route of administration: Oral Commercially available Temozolomide |
Timeline
- Start date
- 2025-08-15
- Primary completion
- 2026-10-30
- Completion
- 2027-02-28
- First posted
- 2025-04-17
- Last updated
- 2025-11-12
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06931626. Inclusion in this directory is not an endorsement.